ArticleInternational journal of molecular sciences2022
NAD
Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 31 citations in OpenAlex.
- Investigating the effects of nicotinamide mononucleotide administration on testicular apoptosis, and mitochondrial function in doxorubicin-treated rats.Molecular biology reports · 2026Article
- Cellular Senescence and Aging: Mechanisms, Disease Convergence, and Therapeutic Frontiers.MedComm · 2026Review
- Therapeutic Potential of Mitochondrial Transplantation with Focus on DBD.International journal of molecular sciences · 2026Review
- Identification and functional analysis of NADFrontiers in genetics · 2026Article
- The role of NADnpj metabolic health and disease · 2025Review
- Nicotinamide riboside supplementation protects against maternal diabetes-associated decline in oocyte quality.Reproduction (Cambridge, England) · 2025Article
- Network Pharmacology Combined With Metabolomics Reveals the Mechanism of Yangxuerongjin Pill Against Type 2 Diabetic Peripheral Neuropathy in Rats.Drug design, development and therapy · 2025Article
- Nicotinamide Mononucleotide Restores NADAntioxidants (Basel, Switzerland) · 2024Article
- Administration of AICAR, an AMPK Activator, Prevents and Reverses Diabetic Polyneuropathy (DPN) by Regulating Mitophagy.International journal of molecular sciences · 2024Article
- Skin keratinocyte-derived SIRT1 and BDNF modulate mechanical allodynia in mouse models of diabetic neuropathy.Brain : a journal of neurology · 2024Article
- Augustus Waller's foresight realized: SARM1 in peripheral neuropathies.Current opinion in neurobiology · 2024Review
- Cell metabolism pathways involved in the pathophysiological changes of diabetic peripheral neuropathy.Neural regeneration research · 2024Review
- NADInternational journal of molecular sciences · 2024Article
- Identification and validation of NAD+ metabolism-related biomarkers in patients with diabetic peripheral neuropathy.Frontiers in endocrinology · 2024Article
- NADAntioxidants & redox signaling · 2023Review
- Nicotinamide Riboside, a Promising Vitamin BMolecules (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
Axon degeneration in diabetic peripheral neuropathy (DPN) is associated with impaired NAD
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.